ONCOGENEX PHARMACEUTICALS IN's ticker is OGXI and the CUSIP is 68230A106. A total of 27 filers reported holding ONCOGENEX PHARMACEUTICALS IN in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $0 | – | 1,405 | 0.0% | 0.00% | – |
| Q1 2017 | $0 | – | 1,405 | +28000.0% | 0.00% | – |
| Q4 2016 | $0 | – | 5 | 0.0% | 0.00% | – |
| Q3 2016 | $0 | – | 5 | -66.7% | 0.00% | – |
| Q2 2016 | $0 | – | 15 | -95.2% | 0.00% | – |
| Q1 2016 | $0 | – | 310 | +30900.0% | 0.00% | – |
| Q4 2015 | $0 | -100.0% | 1 | -100.0% | 0.00% | – |
| Q3 2015 | $78,000 | -70.7% | 35,351 | -69.1% | 0.00% | – |
| Q2 2015 | $266,000 | +6550.0% | 114,434 | +5180.8% | 0.00% | – |
| Q1 2015 | $4,000 | -95.5% | 2,167 | -94.4% | 0.00% | – |
| Q4 2014 | $88,000 | – | 38,618 | +87668.2% | 0.00% | – |
| Q3 2014 | $0 | -100.0% | 44 | -100.0% | 0.00% | – |
| Q2 2014 | $688,000 | +368.0% | 184,550 | +1362.9% | 0.00% | – |
| Q1 2014 | $147,000 | +539.1% | 12,615 | +344.3% | 0.00% | – |
| Q4 2013 | $23,000 | -89.5% | 2,839 | -88.1% | 0.00% | – |
| Q3 2013 | $220,000 | – | 23,836 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 396,104 | $400,000 | 0.42% |
| Ancora Advisors LLC | 50,865 | $51,000 | 0.01% |
| EAGLE GLOBAL ADVISORS LLC | 145,710 | $146,000 | 0.00% |
| Acrospire Investment Management LLC | 5,200 | $5,000 | 0.00% |
| A.R.T. Advisors, LLC | 57,954 | $57,000 | 0.00% |
| Renaissance Technologies | 876,100 | $876,000 | 0.00% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 4,600 | $5,000 | 0.00% |
| Cutler Group LLC / CA | 11,048 | $11,000 | 0.00% |
| PANAGORA ASSET MANAGEMENT INC | 133,846 | $134,000 | 0.00% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 46,100 | $46,000 | 0.00% |